0000950170-24-003650.txt : 20240110 0000950170-24-003650.hdr.sgml : 20240110 20240110163015 ACCESSION NUMBER: 0000950170-24-003650 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240109 FILED AS OF DATE: 20240110 DATE AS OF CHANGE: 20240110 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Valamehr Bahram CENTRAL INDEX KEY: 0001748177 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36076 FILM NUMBER: 24526915 MAIL ADDRESS: STREET 1: C/O FATE THERAPEUTICS, INC. STREET 2: 3535 GENERAL ATOMICS COURT, STE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: FATE THERAPEUTICS INC CENTRAL INDEX KEY: 0001434316 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 651311552 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12278 SCRIPPS SUMMIT DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92131 BUSINESS PHONE: 858.875.1803 MAIL ADDRESS: STREET 1: 12278 SCRIPPS SUMMIT DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92131 4 1 ownership.xml 4 X0508 4 2024-01-09 0001434316 FATE THERAPEUTICS INC FATE 0001748177 Valamehr Bahram C/O FATE THERAPEUTICS, INC. 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 false true false false Chief R&D Officer false Common Stock 2024-01-09 4 S false 11271 4.38 D 158069 D Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 6,250 shares of Common Stock underlying RSUs granted to the Reporting Person on January 8, 2020, 4,503 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021, and 8,326 shares of Common Stock underlying RSUs granted to the Reporting Person on January 25, 2022. These sales were made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell to cover" transactions and do not represent discretionary trades by the Reporting Person. Represents the weighted average sale price of the shares sold ranging from $4.01 to $4.50 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. /s/ Cindy Tahl, as Attorney-in-Fact 2024-01-10